|
Sinusitis 5.0% 4.3% 4.0% 5.4% 5.8%
Upper respiratory tract infection 8.1% 6.7% 9.9% 9.8% 9.9%
Skin Rash 2.2% 2.1% 2.1% 1.3% 1.2%
___________________________________________________________ In placebo- or active-controlled clinical trials, the discontinuation rate due to adverse events was 7.1% for patients receiving CELEBREX and 6.1% for patients receiving placebo. Among the most common reasons for discontinuation due to adverse events in the CELEBREX treatment groups were dyspepsia and abdominal pain (cited as reasons for discontinuation in 0.8% and 0.7% of CELEBREX patients, respectively). Among patients receiving placebo, 0.6% discontinued due to dyspepsia and 0.6% withdrew due to abdominal pain. The following adverse events occurred in 0.1 - 1.9% of patients regardless of causality.
CELEBREX (100 - 200 mg BID or 200 mg QD)
Gastrointestinal: Text Continues Below
Constipation, diverticulitis, dysphagia, eructation, esophagitis, gastritis, gastroenteritis, gastroesophageal reflux, hemorrhoids, hiatal hernia, melena, dry mouth, stomatitis, tenesmus, tooth disorder, vomiting
Cardiovascular: Aggravated hypertension, angina pectoris, coronary artery disorder, myocardial infarction General: Allergy aggravated, allergic reaction, asthenia, chest pain, cyst NOS, edema generalized, face edema, fatigue, fever, hot flushes, influenza-like symptoms, pain, peripheral pain Resistance mechanism Herpes simplex, herpes zoster, infection bacterial, infection disorders: fungal, infection soft tissue, infection viral, moniliasis, moniliasis genital, otitis media
Central, peripheral Leg cramps, hypertonia, hypoesthesia, migraine, neuralgia, neuropathy, nervous system: paresthesia, vertigo
Female reproductive: Breast fibroadenosis, breast neoplasm, breast pain, dysmenorrhea, menstrual disorder, vaginal hemorrhage, vaginitis Page: << Prev | 1 | 2 | 3 | 4 | 5 | Next >>
|
.gif)
